GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:006053713 | Endometrium | EEC | muscle tissue development | 82/2168 | 403/18723 | 2.14e-07 | 9.38e-06 | 82 |
GO:000165512 | Endometrium | EEC | urogenital system development | 69/2168 | 338/18723 | 1.70e-06 | 5.18e-05 | 69 |
GO:007200112 | Endometrium | EEC | renal system development | 63/2168 | 302/18723 | 2.24e-06 | 6.59e-05 | 63 |
GO:001470612 | Endometrium | EEC | striated muscle tissue development | 74/2168 | 384/18723 | 6.64e-06 | 1.57e-04 | 74 |
GO:000182212 | Endometrium | EEC | kidney development | 59/2168 | 293/18723 | 1.44e-05 | 2.87e-04 | 59 |
GO:000206416 | Endometrium | EEC | epithelial cell development | 45/2168 | 220/18723 | 9.73e-05 | 1.35e-03 | 45 |
GO:007207313 | Endometrium | EEC | kidney epithelium development | 30/2168 | 136/18723 | 3.55e-04 | 3.90e-03 | 30 |
GO:004269212 | Endometrium | EEC | muscle cell differentiation | 67/2168 | 384/18723 | 3.87e-04 | 4.12e-03 | 67 |
GO:000975513 | Endometrium | EEC | hormone-mediated signaling pathway | 38/2168 | 190/18723 | 5.18e-04 | 5.21e-03 | 38 |
GO:005114613 | Endometrium | EEC | striated muscle cell differentiation | 51/2168 | 283/18723 | 8.71e-04 | 7.97e-03 | 51 |
GO:003510711 | Endometrium | EEC | appendage morphogenesis | 29/2168 | 138/18723 | 1.01e-03 | 8.89e-03 | 29 |
GO:003510811 | Endometrium | EEC | limb morphogenesis | 29/2168 | 138/18723 | 1.01e-03 | 8.89e-03 | 29 |
GO:000182311 | Endometrium | EEC | mesonephros development | 22/2168 | 96/18723 | 1.22e-03 | 1.02e-02 | 22 |
GO:000165711 | Endometrium | EEC | ureteric bud development | 21/2168 | 91/18723 | 1.42e-03 | 1.16e-02 | 21 |
GO:007216311 | Endometrium | EEC | mesonephric epithelium development | 21/2168 | 92/18723 | 1.64e-03 | 1.29e-02 | 21 |
GO:007216411 | Endometrium | EEC | mesonephric tubule development | 21/2168 | 92/18723 | 1.64e-03 | 1.29e-02 | 21 |
GO:004838411 | Endometrium | EEC | retinoic acid receptor signaling pathway | 10/2168 | 31/18723 | 1.89e-03 | 1.45e-02 | 10 |
GO:00613511 | Endometrium | EEC | neural precursor cell proliferation | 29/2168 | 145/18723 | 2.24e-03 | 1.67e-02 | 29 |
GO:004873611 | Endometrium | EEC | appendage development | 33/2168 | 172/18723 | 2.38e-03 | 1.75e-02 | 33 |
GO:006017311 | Endometrium | EEC | limb development | 33/2168 | 172/18723 | 2.38e-03 | 1.75e-02 | 33 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RARB | SNV | Missense_Mutation | | c.184N>C | p.Glu62Gln | p.E62Q | P10826 | protein_coding | deleterious(0.05) | possibly_damaging(0.864) | TCGA-A2-A0SY-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | arimidex | SD |
RARB | SNV | Missense_Mutation | | c.205N>T | p.Pro69Ser | p.P69S | P10826 | protein_coding | deleterious(0.02) | possibly_damaging(0.839) | TCGA-AN-A041-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RARB | SNV | Missense_Mutation | | c.505N>C | p.Glu169Gln | p.E169Q | P10826 | protein_coding | tolerated(0.06) | benign(0.213) | TCGA-AN-A049-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RARB | SNV | Missense_Mutation | | c.434G>A | p.Gly145Glu | p.G145E | P10826 | protein_coding | deleterious(0) | possibly_damaging(0.903) | TCGA-B6-A0IN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
RARB | SNV | Missense_Mutation | | c.206N>T | p.Pro69Leu | p.P69L | P10826 | protein_coding | deleterious(0.02) | possibly_damaging(0.887) | TCGA-C8-A132-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RARB | SNV | Missense_Mutation | | c.860N>A | p.Arg287Gln | p.R287Q | P10826 | protein_coding | deleterious(0.02) | possibly_damaging(0.812) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
RARB | SNV | Missense_Mutation | | c.1173N>C | p.Leu391Phe | p.L391F | P10826 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-C5-A1BK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
RARB | SNV | Missense_Mutation | | c.440N>T | p.Ser147Phe | p.S147F | P10826 | protein_coding | deleterious(0) | probably_damaging(0.968) | TCGA-C5-A7CL-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | PD |
RARB | SNV | Missense_Mutation | | c.1058N>C | p.Lys353Thr | p.K353T | P10826 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
RARB | SNV | Missense_Mutation | | c.339G>C | p.Met113Ile | p.M113I | P10826 | protein_coding | deleterious(0) | possibly_damaging(0.794) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5915 | RARB | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | agonist | 53801005 | | |
5915 | RARB | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | agonist | CHEMBL464 | ETRETINATE | |
5915 | RARB | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | agonist | 135650917 | | |
5915 | RARB | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | | PMID27336223-Compound-7 | | |
5915 | RARB | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | agonist | 178102082 | ADAPALENE | |
5915 | RARB | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | | Tamibarotene | TAMIBAROTENE | |
5915 | RARB | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | | RETINOIC ACID | | 17001699 |
5915 | RARB | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | agonist | CHEMBL1657 | TAZAROTENE | |
5915 | RARB | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | | LGD-1550 | | |
5915 | RARB | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | agonist | 178103534 | TAZAROTENE | |